VERA•benzinga•
Vera Therapeutics Says Atacicept ORIGIN Phase 3 Trial Meets Primary Endpoint Of Reduction In UPCR For IgAN Treatment; Vera Currently Plans To Submit BLA For Accelerated Approval To FDA In 4Q 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga